Biocon Biologics India Ltd., a fully integrated pure play biosimilars company, headquartered in Bangalore, India has signed a Memorandum of Understanding (MoU) with two municipalities in the Philippines and social enterprise reach52 to enable affordable access to quality insulins in the country.
Biocon Biologics India Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), provides insulins and analogs to people with diabetes across the world.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.